TY - JOUR
T1 - Laboratory and clinical studies of sparfloxacin
AU - Kinjo, Yuutoku
AU - Furugen, Kyouko
AU - Irabu, Yuei
AU - Fukuhara, Hiroshi
AU - Nakamura, Hiroaki
AU - Kaneshima, Hiroshi
AU - Simoji, Katsuyoshi
AU - Kitsukawa, Keizou
AU - Sigeno, Yoshiteru
AU - Saito, Atsushi
AU - Nakasone, Isamu
AU - Taira, Shinko
AU - Kusano, Nobuchika
AU - Hokama, Seitetsu
AU - Morishima, Akihiro
PY - 1991
Y1 - 1991
N2 - We performed laboratory and clinical evaluations of sparfloxacin, a new oral quinolone, with the following results. 1 ) Antimicrobial activity The minimum inhibitory concentrations (MICs) of sparfloxacin for a total of 309 clinically isolated strains were determined and compared with those of tosufloxacin, ofloxacin, and ciprofloxacin, using the MIC-2000 system. Sparfloxacin had wide antimicrobial activities to clinically isolated strains except methicillin-sensitive Staphylococcus aureus (MSSA), methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa. Especially, sparfloxacin showed better MICsto Streptococcus pneumoniae than the compared antimicrobial agents. 2 ) Clinical efficacy Sparfloxacin (300 mg/day) was administered to 1 patient with bacterial pneumonia and 1 patient with chronic bronchitis two times per day. Four patients with chronic bronchitis were treated with sparfloxacin (300 mg) in once a day medication. Clinical responses were excellent in 1 patient, and good in 5 patients. Clinical efficacy rate was 100%. One strain of Haemophilus influenzae was isolated and eradicated. Side effects, and abnormally altered laboratory findings were not observed in all patients.
AB - We performed laboratory and clinical evaluations of sparfloxacin, a new oral quinolone, with the following results. 1 ) Antimicrobial activity The minimum inhibitory concentrations (MICs) of sparfloxacin for a total of 309 clinically isolated strains were determined and compared with those of tosufloxacin, ofloxacin, and ciprofloxacin, using the MIC-2000 system. Sparfloxacin had wide antimicrobial activities to clinically isolated strains except methicillin-sensitive Staphylococcus aureus (MSSA), methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa. Especially, sparfloxacin showed better MICsto Streptococcus pneumoniae than the compared antimicrobial agents. 2 ) Clinical efficacy Sparfloxacin (300 mg/day) was administered to 1 patient with bacterial pneumonia and 1 patient with chronic bronchitis two times per day. Four patients with chronic bronchitis were treated with sparfloxacin (300 mg) in once a day medication. Clinical responses were excellent in 1 patient, and good in 5 patients. Clinical efficacy rate was 100%. One strain of Haemophilus influenzae was isolated and eradicated. Side effects, and abnormally altered laboratory findings were not observed in all patients.
UR - http://www.scopus.com/inward/record.url?scp=0025833129&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0025833129&partnerID=8YFLogxK
U2 - 10.11250/chemotherapy1953.39.Supplement4_378
DO - 10.11250/chemotherapy1953.39.Supplement4_378
M3 - Article
AN - SCOPUS:0025833129
VL - 39
SP - 378
EP - 384
JO - Chemotherapy
JF - Chemotherapy
SN - 0009-3165
ER -